Coronary revascularization: Which, whom, how and when?;Rivascolarizzazione coronarica: Quale, a chi, come e quando?

Italian Heart Journal, Supplement

Volumn 6, Issue 3, 2005, Pages

  Casella, Gianni ^a   Pasquale, Giuseppe Di ^a  

^a MAGGIORE HOSPITAL   (Italy)

Author keywords

Acute coronary syndromes; Coronary revascularization; Prognosis; Risk

Indexed keywords

ACUTE CORONARY SYNDROME; CONFERENCE PAPER; CONSERVATIVE TREATMENT; HEALTH CARE; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ACUTE DISEASE; ANGINA, UNSTABLE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PATIENT SELECTION; PRACTICE GUIDELINES; SYNDROME;

EID: 29244462001     PISSN: 15903796     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-72.
2. Bertrand ME, Simoons ML, Fox KA, et al, for the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina). Circulation 2002; 106: 1893-900.
4. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary interventions (revision of the 1993 PTCA guidelines) - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001; 37: 2215-39.
5. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease Investigators. Lancet 1999; 354: 708-15.
6. Cannon CP, Weintraub WS, Demopoulos LA, et al, for the TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87.
7. White CJ, Ramee SR, Collins TJ, et al. Coronary thrombi increase PTCA risk. Angioscopy as a clinical tool. Circulation 1996; 93: 253-8.
8. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.
9. Simoons ML, for the GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-24.
10. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000; 101: 2557-67.
11. Peterson ED, Pollack CV Jr, Roe MT, et al, for the National Registry of Myocardial Infarction (NRMI) 4 Investigators. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol 2003; 42: 45-53.
12. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-98.
13. O'Neill WW, Dixon SR. The year in interventional cardiology. J Am Coll Cardiol 2004; 43: 875-90.
14. Boden WE. "Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era. J Am Coll Cardiol 2003; 41 (Suppl S): 113S-122S.
15. Fox KA, Poole-Wilson PA, Henderson RA, et al, for the Randomized Intervention Trial of Unstable Angina Investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA-3 randomised trial. Lancet 2002; 360: 743-51.
16. Wallentin L, Lagerqist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary Artery Disease. Lancet 2000; 356: 9-16.
17. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit. Guidelines for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. Heart 2001; 85: 133-42.
18. Lopez-Bescos L, Fernandez-Ortiz A, Bueno Zamora H, et al. Clinical practice guidelines of the Spanish Society of Cardiology on unstable angina/infarction without ST elevation. Rev Esp Cardiol 2000; 53: 838-50.
19. Bavry AA, Kumbhani DJ, Quiroz R, Ramchandani SR, Kenchaiah S, Antman EM. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. Am J Cardiol 2004; 93: 830-5.
20. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998; 338: 1785-92.
21. Di Chiara A, Chiarella F, Savonitto S, et al, on behalf of the BLITZ Investigators. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J 2003; 24: 1616-29.
22. Pavesi PC, Ottani F, Bologna F, Gaddi O, Alboni P, Galvani M, 61 nome dei Ricercatori dello Studio AI-CARE2. Epidemiologia delle sindromi coronariche acute nelle cardiologie dell'Emilia Romagna: lo studio AI-CARE2. Ital Heart J Suppl 2003; 4: 733-44.
23. De Servi S, Cavallini C, Dellavalle A, et al, for the ROSAI-2 Investigators. Non-ST-elevation acute coronary syndrome in the elderly: treatment strategies and 30-day outcome. Am Heart J 2004; 147: 830-6.
24. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: 583-91.
25. Lemos PA, Lee CH, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003; 41: 2093-9.
26. Niemela K, Vikman S. Early invasive therapy of non-ST-elevation acute coronary syndromes - combined with up-stream antiplatelet therapy: yes - but how early? Eur Heart J 2003; 24: 1383-4.
27. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 1593-9.
28. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338: 1498-505.
29. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338: 1488-97.
30. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339: 436-43.
31. Ronner E, Boersma E, Akkerhuis KM, et al. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J 2002; 23: 239-46.
32. Hamm CW, Bertrand ME, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 2001; 358: 1533-8.
33. Savonitto S, Klugmann S. Sindromi coronariche acute senza sopraslivellamento del tratto ST. Dai trial clinici, alle linee guida, alla pratica clinica in Italia: necessità di chiudere il cerchio. Ital Heart J Suppl 2004; 5: 167-76.
34. Ohman ME, Roe MT, Smith SC Jr, et al, for the CRUSADE Investigators. Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J 2004; 148 (Suppl): S34-S39.
35. Califf RM, Faxon DP. Need for centers to care for patients with acute coronary syndromes. Circulation 2003; 107: 1467-70.
36. Pancaldi LG, Tortorici G, Casella G, et al. Efficacia e sicurezza dell'invio e rientro dei pazienti con sindrome coronarica acuta (SCA) presso un'emodinamica interventistica out site con modalità "va e vieni". (abstr) Ital Heart J 2004; 5 (Suppl 5): 4S.